The new Instituto Bernabeu Group newsletter is now available, dedicated to our last reserach work accepted at FFER congress 2018.
Instituto Bernabeu has submitted three items of research work to the French Federation of Reproduction Studies (FFER) Congress that will be held in the French city of Lyon between 12th and 14th September. The event will bring together over 600 experts from all over the world who will exchange information on the latest updates in fertility and reproduction.
Research performed by Instituto Bernabeu has looked into whether fresh transfer or deferred transfer through cryopreservation followed by defrosting is the best strategy for carrying out pre-implantation genetic diagnosis for aneuploidies (PGT-A).
As a part of our continuous training programme, an intensive theoretical and practical seminar entitled ‘Advanced Workshop in Embryo Biopsy: Techniques and tips for usage’ will take place. The workshop is aimed at reproduction biologists who are specialised in micro-handling techniques.
During assisted reproduction treatment, conventional ovarian stimulation is performed over the first few days of the menstrual cycle. However, recent research shows that it can begin on any day of the menstrual cycle. The advantage is a decrease in the total time before treatment can begin. During the research, the oocyte retrieval results using the two strategies were similar.
Instituto Bernabeu has carried out research work with the aim of understanding if it is possible to predict the success of a cycle of egg donation by analysing two parameters: the number of mature donated oocytes obtained following ovarian stimulation and the quantity that are eventually fertilised.
Based on the positive results obtained, research performed by Instituto Bernabeu in Albacete entertains attempting ovarian stimulation in patients with low oocyte retrieval levels. The strategy is a step taken prior to egg donation.
With the incorporation of genetic techniques, it has been possible to identify a greater number of microorganisms that cannot be analysed with a normal microbiological culture and that make up the vaginal microbiome. A powerful tool to identify the microbiome are the massive sequencing techniques. The analysis of the microbiome is important since, among other things, in the field of reproductive medicine it is possible to detect if there is a microorganism that can facilitate or hinder the implantation of the embryo.
Since one of the parameters that enable us to measure assisted reproductive treatment efficiency is embryo morphology, its research is highly critical.
A study performed in the molecular biology and genetics laboratory at Instituto Bernabeu, IB Biotech, and submitted to the Spanish Fertility Society (SEF) congress has concluded that there is an increased risk of embryo abnormalities in chromosomal segments in young women.
Research carried out by Instituto Bernabeu has concluded that the use of heparin, an anticoagulant drug, improves prognosis in courses of in vitro fertilisation treatment (IVF) and ICSI (intracytoplasmic sperm injection) in patients who have experienced recurrent pregnancy loss or repeated implantation failure.
Instituto Bernabeu has submitted research work managed by Belén Lledó, Director of the clinic's Genetics Unit, to the Spanish Fertility Society (SEF) congress. The research involved analysis of mitochondrial DNA (mtDNA) in embryos and its link to the success of in vitro fertilisation treatment (IVF).
Instituto Bernabeu has submitted research work to the 32nd Spanish Fertility Society (SEF) National Congress held in Madrid. The aim of the study is to gain an understanding of drugs under conditions that differ from authorised use for courses of in vitro fertilisation (IVF) in patients with poor response, the frequency with which they are used in these cases and a review of the legal side to their administration. The research work is entitled: ‘Use of drugs under different conditions to those authorised within the framework of a course of in vitro fertilisation: a review of legal aspects and experience of use in patients with poor ovarian response.’
Parents' main aim in life is to ensure that their children are born healthy and that they, as parents, have the chance to ensure this happens. With this in mind, the Rafael Bernabeu Foundation makes its resources and research available so that people faced with health issues and also financial difficulties can try for children who are free of the illness they are carrying. The Rafael Bernabeu Foundation, Instituto Bernabeu's social wellness programme has, for many years, been offering preferential service when providing treatment for associations and social entities, including members of the Association in Support of the Mentally Ill of Alicante (Asociación Pro Discapacitados Psíquicos de Alicante, APSA).
‘Patients with poor ovarian response have a different distribution in the follicle-stimulating hormone (FSHR) genotype.’ This is the title of the research work that Instituto Bernabeu gynaecologist, Yasmina Ben-Aicha, presented at the Spanish Fertility Society (SEF) congress. The leading national infertility event’s scientific committee has accepted a total of 16 pieces of Instituto Bernabeu research work, 12 of which are oral presentations given by their lead authors.
The Instituto Bernabeu Group will once again attend the world's most significant reproductive medicine congress, both in terms of the work that is presented and in the number of specialists who attend.
Scientific research carried out by Instituto Bernabeu looked into the chances of a successful pregnancy using implanted embryos with chromosome mosaicism. It is a controversial issue because these embryos have a chromosomal abnormality in some cells and, until recently, these abnormalities were not detected. Thanks to current high-precision next-generation sequencing or NGS techniques and array-CGH during pre-implantation diagnosis for detecting aneuploidies, chromosomal abnormalities can be detected with precision in chromosome segments as well as in complete chromosomes.
Once again this year, Instituto Bernabeu was present at the 6th edition of the Mediterranean Forum, a national gathering organised by Merck under the title ‘Human Reproduction’ where gynaecologists learn about the latest in the field. The Director of the Reproduction and Genetics Guidance Unit at Instituto Bernabeu, Dr Andrea Bernabeu, was present at the event where exchanges on very latest in the field of reproductive medicine take place. Her presentation was on new forms of ovarian stimulation. The gynaecologist covered new approaches using personalised treatment, new protocols and new means of administering pharmaceutical drugs.
The group of clinic’s aim, as it travelled to France in order to hold an informative event, is to make Instituto Bernabeu known beyond our frontiers and open up new horizons to foreign patients who are unable to get pregnant naturally.